We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- The use of animal models
- A prioritization process from mice to humans
- The non-obese diabetic (NOD) mouse
- Incidence can vary depending on site/colony
- Reproducibility in the NOD model
- Reproducibility: a case study (1)
- Reproducibility: a case study (2)
- 3 sites and dose response kinetics
- Increasing stringency level options
- Predictive potential of biomarkers: autoantibodies
- Predictive potential of biomarkers: CD8+ T cells
- Alternate models: the RIP-LCMV mouse
- Intravital imaging of CTLs killing islet cells
- Stringent testing of combination therapies
- Ongoing general challenges
- Mitigation actions and consequences
- Recommendations, moving forward
- Sample power calculations
- Standardizing statistical methods
- Conclusions and recommendations
Topics Covered
- The use of animal models
- Strategy T1D: a prioritization process from mice to humans
- The non-obese diabetic (NOD) mouse model: reproducibility, increasing stringency level options, predictive potential of biomarkers
- Alternate models: The RIP-LCMV mouse
- Ongoing general challenges, mitigation actions & consequences
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
von Herrath, M. (2015, February 11). Development of immunotherapies for type 1 diabetes. Value and limitations of mouse models. [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 8, 2024, from https://doi.org/10.69645/OHKL1990.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. von Herrath is an employee of Novo Nordisk.
Other Talks in the Series: Animal Models in Biomedical Research
Transcript
Please wait while the transcript is being prepared...
0:00
Hello, everybody.
I'm Matthias von Herrath, and I'm
a professor at La Jolla Institute,
and also a vice present
for Novo Nordisk
for an approach that develops
therapeutics for type 1 diabetes.
We'll be talking about the value
and limitation of mouse models
in general today, but I will
construct the talk with an area
that I know best, which is the
development of immune therapies
for type 1 diabetes.
And these examples I will give
you in the course of the talk
should hopefully also be very
useful for the use of animal models
in other therapeutic areas.
0:45
It's a timely situation because,
especially in diabetes, but also
in other applications of
biology, there has always
been a lot of controversy
surrounding the use of animal
models, whether they
reflect the human situation,
whether they don't reflect
the human situation,
when they reflect
the human situation.
And really, what you
will see from the talk,
and as my position on
this whole subject,
is that it's very valuable to use
animal models, and in this case
mouse models, which we will
be talking about today,
if they are used in
the correct fashion.
And hopefully from the ensuing talk,
you can gather some advice on how
this can be done, and
also to realize that it's
very important in the
design of experiments
and in the whole translation
of the process from animal
models to the human bedside to
know the limitation of such animal
models.
I should also add that
I will not discuss,
because I also work for a
pharmaceutical company, Novo
Nordisk, I will not discuss
any drugs or approaches
from Novo Nordisk that are
specific for the company,
and that will be my disclaimer.
Hide